EchoGo® Featured in Hot Line and Late-Breaking Science Sessions at ESC Congress 2024

Oxford, UK – July 9, 2024 – Utromics, creators of EchoGo^®, an AI-driven diagnostics platform for echocardiography, is set to unveil data demonstrating significant advancements in cardiovascular care at the upcoming European Society of Cardiology (ESC) conference, held in London from August 30 to September 2, 2024. A particular highlight will be two Late-Breaking Science sessions, including an ESC Hot Line Session, and two abstract presentations. 

These sessions will showcase new clinical trial data from Ultromics’ EchoGo^® platform, and its specialized modules for detecting Coronary Artery Disease, HFpEF and Cardiac Amyloidosis. The session details are as follows: 

Ultromics will present the PROTEUS study, the first prospective randomized controlled trial (RCT) to evaluate an AI-powered device for stress echocardiography, and its impact on the patient care pathway. 

During the Hot Line session, Ross Upton, PhD., will present the primary results of the PROTEUS trial, followed by an independent discussant, and chaired by a panel of trialists. Ross Upton, PhD., will also participate in an interview for ESC TV to discuss the key takeaways of the trial. 
 
The objective of the PROTEUS trial was to determine whether AI-augmented decision-making was non-inferior to standard clinical decision-making in selecting patients for invasive coronary angiography post-stress echocardiography. 

Late-Breaking Science: AI-powered Echocardiographic Screening for Cardiac Amyloidosis  Echocardiographic Screening for Cardiac Amyloidosis Using Artificial Intelligence: A Multi-Site Study for Algorithm Training and External Validation  Patricia Pellikka, M.D., Vice Chair of the Department of Cardiovascular Medicine at the Mayo Clinic, Betty Knight Scripps Professor of Cardiovascular Diseases, and Editor-in-Chief of JASE.  📍 Sunday, September 1, 9:00 AM (BST) - San Marino Room

This session will highlight the diagnostic performance of EchoGo^® Amyloidosis, and its potential to revolutionize cardiac amyloidosis screening. The objective was to develop and validate an AI algorithm for detecting cardiac amyloidosis using an echocardiographic clip. 
 
In addition to the Late-Breaking sessions, Ambarish Pandey, MD, MSCS, FAHA., will present two abstracts focusing on the EchoGo^® Heart Failure platform's performance in detecting clinical and sub-clinical HFpEF. 

Abstract Posters: AI-powered Detection of HFpEF: A Case-Control  Diagnostic and Prognostic Evaluation of an Echocardiography-based Artificial Intelligence Algorithm for Detecting HFpEF: A Case-Control Analysis Presenter: Ambarish Pandey, MD, MSCS, FAHA, Associate Professor of Internal Medicine, Divisions of Cardiology and Geriatrics, Medical Director, HFpEF Program, UT Southwestern Medical Center, Dallas, Texas 75204 Date and Time: Friday, 30 August, 11:00 AM (BST)  Session Location: Moderated ePosters, Station 2  AI-powered Detection of Subclinical HFpEF in Older Adults  Poster Title: Performance of an Automated Echocardiographic Artificial Intelligence Model for Detecting Subclinical Heart Failure with Preserved Ejection Fraction (HFpEF) in Community-dwelling Older Adults  Presenter: Ambarish Pandey, MD, MSCS, FAHA, Associate Professor of Internal Medicine, Divisions of Cardiology and Geriatrics, Medical Director, HFpEF Program, UT Southwestern Medical Center, Dallas, Texas 75204  Date and Time: Saturday, 31 August, 5:00 PM (BST)  Location: Moderated ePosters, Station 2

Ultromics invites attendees to join these sessions and explore how AI-driven solutions are transforming cardiac care.  

The Ultromics team will be attending the ESC 2024 conference and can answer any questions you may have about our technology and research. We will be located in the digital health section, so please stop by our booth to learn more. 
 
To schedule a meeting with Ultromics during the event, please visit this link. For more details, For more information, visit our website here. 

Follow us on LinkedIn and X⤵